Developed for consolidated DNA and RNA enrichment and integrated analysis, this solution has a lower sample input requirement that is ≥50% less than conventional approaches for increased compatibility with samples of limited availability. It also enables a lower overall sequencing requirement compared to separate DNA and RNA approaches, resulting in reduced per-sample costs. The QIAseq Pan-cancer Multimodal Panel provides a sample to sequencing workflow that is up to 2 days faster, with more than 50 fewer steps than similar protocols
Recent advances in NGS chemistries, platforms and bioinformatics pipelines are enabling users to efficiently interrogate biological samples for changes in DNA and RNA. Current approaches, however, require the use of 2 separate workflows to prepare libraries from separate DNA and RNA isolates. Limitations of such approaches include:
To overcome the limitations associated with current approaches, the QIAseq Pan-cancer Multimodal Panel starts with total nucleic acids (or DNA and RNA) as input, and generates UDI-containing, Illumina-compatible targeted DNA and RNA libraries using a single-day, consolidated workflow. In addition, the QIAseq Pan-cancer Multimodal Panel has been designed for use with low-yield and poor-quality biological samples.
The QIAseq Pan-cancer Multimodal Panel workflow can be used to prepare sequencing-ready libraries in a single day. The library insert size is approximately 150 bp, making the QIAseq Pan-cancer Multimodal Panel highly compatible with low-quality samples, such as FFPE samples.
Learn more about the unique and innovative workflow of the QIAseq Pan-cancer Multimodal Panel.
The QIAseq Pan-cancer Multimodal Panel can be used to reliably detect DNA and RNA biomarkers using a consolidated workflow from total nucleic acids. The ability of the QIAseq Pan-cancer Multimodal Panel to simultaneously detect DNA and RNA biomarkers has been benchmarked against two separate workflows (namely, QIAseq Targeted DNA and QIAseq Targeted RNAscan Panels).
The QIAseq Pan-cancer Multimodal Panel can be used to interrogate different types of biomarkers using a consolidated workflow from total nucleic acids, which can be isolated using dedicated sample isolation protocols that have been developed specifically for the QIAseq Pan-cancer Multimodal Panel.
This innovative technology is well suited for addressing the challenges in comprehensive genomic profiling (CGP), where different types of biomarkers are assessed from a single sample. In addition, it is useful for biomarker discovery as multi-omic approaches and integrated analysis are key to providing deeper and more relevant insights.